《大行》花旗:阿斯利康20亿美元投资SMMT印证依沃西实力 维持康方生物(09926.HK)“买入”评级

阿斯达克财经
Yesterday

花旗发表报告指,阿斯利康(AZN.US)  宣布向Summit(SMMT.US)  作出20亿美元策略性股权投资,并就ivonescimab(依沃西)(PD-1/VEGF)与Sone-Ve在胃肠道肿瘤的联合用药达成临床合作。该行认为,此交易与阿斯利康把其扩大中的ADC组合定位为未来肿瘤治疗方案骨干的策略一致。该行指出,Summit透过与康方生物(09926.HK) 的合作,取得依沃西在中国以外...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10